106 related articles for article (PubMed ID: 1494491)
1. The role of cholecystokinin (CCK8) on glucose production and elimination, and on plasma insulin and glucose in rats.
Verspohl EJ; Zoll C; Wahl MA; Ammon HP
Peptides; 1992; 13(6):1091-5. PubMed ID: 1494491
[TBL] [Abstract][Full Text] [Related]
2. Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L 364718, a specific inhibitor of CCK-receptor binding.
Rossetti L; Shulman GI; Zawalich WS
Diabetes; 1987 Oct; 36(10):1212-5. PubMed ID: 3308589
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin is not a major determinant for the changes in beta-cell function seen after pancreatico-biliary diversion in rats.
Gasslander T; Lilja I; Smeds S; Lundquist I; Ihse I
Diabetes Res; 1991 Nov; 18(3):135-42. PubMed ID: 1841824
[TBL] [Abstract][Full Text] [Related]
4. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.
Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Gettys TW; Taylor IL; Rushakoff RJ; Williams VC; Coker LD
J Clin Endocrinol Metab; 1990 May; 70(5):1312-8. PubMed ID: 2186058
[TBL] [Abstract][Full Text] [Related]
5. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
Durieux C; Ruiz-Gayo M; Roques BP
Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
[TBL] [Abstract][Full Text] [Related]
6. Fasting and L-364,718 prevent cholecystokinin-induced elevations of plasma insulin levels.
Reagan JE; Robinson JL; Lotti VJ; Goldman ME
Eur J Pharmacol; 1987 Dec; 144(2):241-3. PubMed ID: 3325297
[TBL] [Abstract][Full Text] [Related]
7. Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice.
Karlsson S; Ahrén B
Acta Physiol Scand; 1989 Mar; 135(3):271-8. PubMed ID: 2648765
[TBL] [Abstract][Full Text] [Related]
8. The cholecystokinin antagonist L-364,718 inhibits the action of cholecystokinin but not bombesin on rat pancreatic secretion in vivo.
Anderson L; Dockray GJ
Eur J Pharmacol; 1988 Feb; 146(2-3):307-11. PubMed ID: 3371402
[TBL] [Abstract][Full Text] [Related]
9. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity.
Soar J; Hewson G; Leighton GE; Hill RG; Hughes J
Pharmacol Biochem Behav; 1989 Jul; 33(3):637-40. PubMed ID: 2587606
[TBL] [Abstract][Full Text] [Related]
10. Proglumide antagonizes cholecystokinin effects on plasma glucose and insulin in rats in vivo.
Verspohl EJ; Wunderle G; Ammon HP
Eur J Pharmacol; 1988 Jul; 152(1-2):121-8. PubMed ID: 3208828
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic atrophy in rats produced by the cholecystokinin-A receptor antagonist devazepide.
Nylander AG; Chen D; Ihse I; Rehfeld JF; Håkanson R
Scand J Gastroenterol; 1992 Sep; 27(9):743-7. PubMed ID: 1411279
[TBL] [Abstract][Full Text] [Related]
12. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
[TBL] [Abstract][Full Text] [Related]
13. Stimulatory effects of cholecystokinin on isolated perifused islets inhibited by potent and specific antagonist L 364718 [corrected].
Zawalich WS; Diaz VA; Zawalich KC
Diabetes; 1988 Oct; 37(10):1432-7. PubMed ID: 3046973
[TBL] [Abstract][Full Text] [Related]
14. Effects of endogenous and exogenous cholecystokinin and of infusion with the cholecystokinin antagonist L-364,718 on pancreatic and gastrointestinal growth.
Axelson J; Håkanson R; Ihse I; Lilja I; Rehfeld JF; Sundler F
Scand J Gastroenterol; 1990 May; 25(5):471-80. PubMed ID: 2359975
[TBL] [Abstract][Full Text] [Related]
15. Effect of L-364,718 on pancreatic endocrine function following partial pancreatectomy.
Presti ME; Niehoff ML; Burton FR; Solomon H; Garvin PJ
J Surg Res; 1996 Aug; 64(2):170-5. PubMed ID: 8812629
[TBL] [Abstract][Full Text] [Related]
16. Endogenous CCK in the control of gastric emptying of glucose and maltose.
Moran TH; Field DG; Knipp S; Carrigan TS; Schwartz GJ
Peptides; 1997; 18(4):547-50. PubMed ID: 9210174
[TBL] [Abstract][Full Text] [Related]
17. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve.
Mercer JG; Lawrence CB
Neurosci Lett; 1992 Mar; 137(2):229-31. PubMed ID: 1374868
[TBL] [Abstract][Full Text] [Related]
19. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.
Liddle RA; Rushakoff RJ; Morita ET; Beccaria L; Carter JD; Goldfine ID
J Clin Invest; 1988 Jun; 81(6):1675-81. PubMed ID: 3290250
[TBL] [Abstract][Full Text] [Related]
20. Role of cholecystokinin in the anorexia produced by duodenal delivery of glucose in rats.
Woltman T; Reidelberger R
Am J Physiol; 1996 Dec; 271(6 Pt 2):R1521-8. PubMed ID: 8997348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
